BB Biotech (BION) Q3 2024 earnings summary

Executive summary

• Q3 2024 saw continued market volatility, with major indices reaching new highs and the US Fed cutting rates for the first time in four years, potentially benefiting biotech capital flows.

• Share price return for the quarter was -9.2% in CHF and -6.7% in EUR, with a net loss of CHF 157 mn in Q3 but a net profit of CHF 16 mn for the first nine months of 2024, a significant turnaround from a CHF 316 mn loss in the same period last year.

• Portfolio adjustments focused on realizing gains from large holdings and reallocating to high-growth companies, maintaining a high investment level at 112.3%.

Financial highlights

• Market capitalization at period end: CHF 2,016.6 mn, down from CHF 2,368.4 mn in 2023.

• Net Asset Value (NAV) at period end: CHF 2,229.0 mn, down from CHF 2,323.2 mn in 2023.

• Profit for the first nine months: CHF 16.2 mn (vs. loss of CHF 206.6 mn in 2023); Q3 net loss: CHF 157 mn.

• Total return for shares YTD: -11.1% in CHF; portfolio performance: +0.3% in CHF.

• Dividend of CHF 2.00 per share paid in March 2024.

Outlook and guidance

• Lower interest rates and improving capital markets are expected to support biotech sector inflows.

• US presidential election and policy changes may impact healthcare and drug pricing.

• Portfolio companies are well-positioned for positive clinical news, approvals, and launches in late 2024.

• Brighter financial market sentiment and a reawakening IPO market may drive renewed investor interest.

• Anticipated increase in M&A activity as big pharma faces patent cliffs.